Berlin

• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• A clinical trial applying Regulatory T cells in kidney transplant recipients to investigate the safety and tolerability as an adjunctive the … Recruiting
  2024-514398-23-00 9 2024-06-10 Solid organ transplantation (Kidney)
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting
  2023-506150-21-00 4 2024-05-29 Celiac Disease
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye … Recruiting
  2023-507677-18-00 9 2024-05-17 Chronic Myeloid Leukemia
• Long-Term Follow-Up of Subjects Treated With NTLA-2002 Recruiting
  2023-507956-56-00 9 2024-05-17 Hereditary Angioedema
• Evaluation of the efficacy and safety of a new gel containing 10 mg/g Clindamycin and 0.25 mg/g Tretinoin vs. the originator Acnatac(R) 10 m … Recruiting
  2023-504552-10-01 5 2024-05-14 Papulopustular acne
• Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting
  2022-501648-14-00 9 2024-05-05 Relapsed or refractory CD19 positive B cell malignancies (adult ALL, a
• Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS) Recruiting
  2022-502743-35-00 4 2024-04-22 Sporadic Amyotrophic Lateral Sclerosis
• Study to learn about the safety of fazirsiran and if it can help people with alpha-1 antitrypsin liver disease with mild liver scarring (fib … Recruiting
  2023-504198-19-00 5 2024-04-18 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people … Recruiting
  2022-502576-23-00 1 2024-04-17 Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive
• Study of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting
  2022-501119-14-01 4 2024-04-16 Ulcerative Colitis
• A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting
  2023-504374-38-00 5 2024-04-12 Locally advanced cervical cancer
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance

Showing 673–696 of 1,776 trials